Yuhan Corp (000100 KS): R&D Endeavors Finally Began to Pay Back; Lazertinib to Drive Future Growth
R&D investment is generating highest-margin earning outlicensing revenue stream. In-house developed drug, lazertinib is the biggest growth engine...
355 Views
CrystalGenomics (083790 KS): Partner’s Clinical Data Presentation Is Not a Buying Opportunity
Partner's clinical trial data presentation at an upcoming conference does not represent upside potential for CrystalGenomics shares.
295 Views
HK Inno.N (INNO KS): On a Solid Growth Path with Blockbuster New Drug K-CAB
K-CAB has already become the no. 1 drug in Korean digestive treatment market. Thus far, K-CAB has marketing partnerships with 24 countries.
549 Views
KRX BBIG Index Rebalance: Krafton, SK Bioscience, SK IE Tech Included (Among Others)
Krafton has been added to the Game index, SK IE Tech added to the Battery index, SK Bioscience to the Bio index. Lots of flow on some names....
330 Views
KRX BBIG Index Rebalance Preview: Worth a Look
There are lots of changes expected to the KRX BBIG indices at the September review. With a large amount of assets tracking the indices, some of the...
655 Views